KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions for drug delivery in home and ambulatory care settings. Its Freedom Syringe Infusion System includes Freedom60 and FreedomEDGE syringe infusion drivers, Precision Flow Rate Tubing, and HigH-Flo Subcutaneous Safety Needle Sets.
Company updates commonly cover quarterly results, revenue guidance, cash flow trends, FDA 510(k) clearances, EU MDR certification, and label expansions, including FreedomEDGE use for RYSTIGGO delivery. News also addresses pharma services and clinical-trial collaborations with biopharmaceutical companies, customization of the Freedom System across drug categories, and governance or leadership succession matters.
KORU Medical Systems (NASDAQ: KRMD) will report its third quarter 2025 financial results on Wednesday, November 12, 2025.
Management will host a conference call and live webcast at 4:30 p.m. ET to discuss results and provide a corporate update. U.S./Canada dial-in is (877) 407-0784; international dial-in is (201) 689-8560. A live and archived webcast will be available via the Investor Relations calendar at www.korumedical.com. The archived webcast will remain accessible for six months.
KORU Medical Systems (NASDAQ: KRMD) has partnered with ForCast Orthopedics to integrate KORU's FreedomEDGE® infusion system into ForCast's Wearable Intra-Articular Infusion System (WIIS) for treating periprosthetic joint infection (PJI).
The collaboration aims to support ForCast's FC001 program, which has received both Orphan Drug Designation and Qualified Infectious Disease Program (QIDP) designation from the FDA. The program targets PJI, a rare but serious complication of joint replacement procedures where bacteria form resistant biofilms on prostheses. Clinical trials are anticipated to begin in 2026.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q2 2025 financial results, achieving a significant milestone with quarterly revenue exceeding $10.2 million, marking a 21% increase year-over-year. The company's core business revenue grew 19% to $9.3 million, while Pharma Services and Clinical Trials revenue surged 42% to $0.9 million.
Key highlights include gross profit of $6.5 million (63.5% margin), improved cash position with quarterly usage of $0.6 million, and the appointment of Adam Kalbermatten as Chief Commercial Officer. The company raised its 2025 revenue guidance to $39.5-$40.5 million, representing 18-20% growth, while maintaining gross margin guidance of 61-63%.
Notable developments include the Freedom Infusion System's expanded indication for Empaveli® in C3G and Primary IC-MPGN treatment, and a new FDA 510(k) submission for use with a rare disease biologic drug.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has granted inducement equity awards to its new Chief Commercial Officer, Adam Kalbermatten. The compensation package includes:
600,000 nonqualified stock options at $3.44 per share granted on August 1, 2025, and 300,000 restricted shares awarded on July 28, 2025. Both awards vest 25% annually over four years, with potential accelerated vesting. The Compensation Committee approved these awards under Nasdaq Listing Rule 5635(c)(4) as part of Kalbermatten's employment agreement dated June 30, 2025.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference.
The Company's management will deliver their presentation on August 13, 2025, at 10:30 am ET. Investors and interested parties can access both the live and archived webcast through the News/Events page in the Investors section of KORU Medical's website.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. U.S. and Canadian participants can dial (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's investor relations website for six months following the event.
KORU Medical Systems (NASDAQ: KRMD) has appointed Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Kalbermatten brings over 20 years of commercial leadership experience in medical devices and pharmaceuticals, joining from Becton Dickinson where he served as VP and GM of Advanced Drug Delivery Systems.
In his new role, Kalbermatten will oversee KORU Medical's global commercial strategy, including marketing, sales, market access, and pharmaceutical customer engagement. His previous experience includes serving as CEO of ZebraSci and holding global leadership positions at Terumo Medical Corporation. He holds engineering degrees from Stevens Institute of Technology and an MBA from Columbia Business School.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q1 2025 financial results, with net revenues reaching $9.6 million, an 18% increase year-over-year. The company's core business grew 21% to $9.4 million, driven by domestic and international expansion. Gross profit increased 19% to $6.0 million, with improved margins of 62.8%.
Key highlights include plans to submit two FDA 510(k) clearances for commercialized drugs with the Freedom Infusion System™ in 2025. The company raised its 2025 revenue guidance to $38.5-39.5 million from $38.0-39.0 million, maintaining gross margin guidance of 61-63% and expecting positive cash flow from operations for 2025.
Despite a quarterly net loss and cash usage of $0.8 million, KORU ended Q1 with $8.7 million in cash. The company's growth was primarily driven by new patient starts, market share gains, and international geographical expansion.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in large volume subcutaneous infusion solutions, has announced it will release its first quarter 2025 financial results on Wednesday, May 7, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. U.S. and Canadian participants can join via (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's website and archived for six months.